Literature DB >> 2789930

Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.

D O Rumiantsev1, V K Piotrovskii, V I Metelitsa, I D Slastnikova, E V Kokurina.   

Abstract

Serum free fractions of nifedipine, verapamil and some of their metabolites were measured in patients with ischaemic heart disease receiving single oral dose and chronic monotherapy and were compared with those obtained in vitro. The percentages of unbound nifedipine and verapamil in vitro (concentration range 50-200 and 150-400 ng ml-1, respectively) were 2.51 and 7.23%, respectively, and did not differ from those found on monotherapy with these drugs (2.05 and 8.08%, respectively), and after single dosing. It is suggested that, during treatment with nifedipine or verapamil, their serum metabolites do not affect binding of the parent drugs to serum proteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789930      PMCID: PMC1379956          DOI: 10.1111/j.1365-2125.1989.tb05438.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Prediction of steady-state verapamil plasma concentrations in children and adults.

Authors:  J G Wagner; A P Rocchini; J Vasiliades
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

3.  Prolongation of verapamil elimination kinetics during chronic oral administration.

Authors:  J B Schwartz; D L Keefe; E Kirsten; R E Kates; D C Harrison
Journal:  Am Heart J       Date:  1982-08       Impact factor: 4.749

4.  Direct determination of hepatic extraction of verapamil in cardiac patients.

Authors:  B G Woodcock; W Schulz; G Kober; N Rietbrock
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

5.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

6.  Factors affecting the plasma protein binding of verapamil and norverapamil in man.

Authors:  C L Yong; R L Kunka; T R Bates
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-11

7.  Verapamil protein binding in patients and in normal subjects.

Authors:  D L Keefe; Y G Yee; R E Kates
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

8.  Reduced verapamil clearance during long-term oral administration.

Authors:  D G Shand; S C Hammill; L Aanonsen; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

9.  Verapamil kinetics in normal subjects and patients with coronary artery spasm.

Authors:  S B Freedman; D R Richmond; J J Ashley; D T Kelly
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

10.  Verapamil disposition kinetics in chronic atrial fibrillation.

Authors:  R E Kates; D L Keefe; J Schwartz; S Harapat; E B Kirsten; D C Harrison
Journal:  Clin Pharmacol Ther       Date:  1981-07       Impact factor: 6.875

View more
  2 in total

Review 1.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

2.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.